Press Release 26 February 2016

Curida teams up with leading Nasal Spray Expert, strengthening Development Services

Curida, a Contract Development and Manufacturing Organization (CDMO) based in Norway, strengthens its Development Services with a strategic partnership with Dr. René Bommer. Dr. Bommer is known for his competency within Nasal Spray and chairs the annual Nasal Drug Delivery conference. He is also a member of the jury panel at CPHI Pharma Awards. In July 2015, Curida acquired a Takeda manufacturing site with more than 25 years of nasal spray manufacturing experience.

Dr. René Bommer commented, “Curida’s holistic business approach to consider the unity of product content and delivery device in the development and in the further manufacturing process puts them into a leading position in the pharmaceutical industry. I am delighted to cooperate with such well-focused company and to contribute actively to the business success of Curida.”

“We are very happy and proud to having Dr. Bommer joining our team. His knowledge and experience within this complex field is impressive. I have already had the fortune to work with him on a project and his blend of technical in-depth knowledge coupled with a commercial mind-set is quite rare and a strong asset”, says Morten Steinvåg, Sales Director at Curida.

Curida’s development expertise covers the full service for the development of nasal and inhalation drug products (OINDP). The cGMP compliant laboratory service includes the extensive performance characterisation studies for nasal and inhalation drug products (OINDP) and other dosage forms provided with a delivery device, such as ophthalmic or topical products.

For the development of generic products, Curida is able to perform the regulatory challenging *in-vitro* bioequivalence studies and is responsible for the relevant CMC documentation for submission to the authorities.

Preservative free, sterile nasal and ophthalmic drug products fitted with multi dose delivery devices become more and more popular. In addition to physical device performance characterisation, Curida develops and validates the microbiological protocols and assesses the microbiological integrity of the product during shelf life and in particular during the in-use period.

Coupled with the manufacturing capabilities, Curida provides a one-stop solution from development to manufacture of drug products combined with a delivery device.

Ref.

FDA Guidance for Industry Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products — Chemistry, Manufacturing, and Controls Documentation U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), July 2002

FDA Guidance for Industry Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Biopharmaceutics. April 2003

EMA Guideline on the Pharmaceutical Quality of Inhalation and Nasal Products, Committee for Medicinal Products for Human Use (CHMP), London, 21 June 2006

For more information contact:

Morten Steinvåg, Sales Director, Curida
E-mail: mst@curida.no
Phone: +47 469 46 469

Dr. René Bommer, General Manager, pharmAccel Consulting
Email: consult@pharmaccel.com
Phone: +49 173 672 5145

About Curida

Curida is a Contract Development and Manufacturing Organization (CDMO) within the Pharmaceutical industry, based in Norway. Curida has core competency in state-of-the-art manufacturing of Liquid Pharmaceuticals based on sterile unit-dose Blow-Fill-Seal (BFS) technology and Nasal Spray. The development expertise covers the full service for the development of nasal drug products, and experience on operational excellence is spanning more than 40 years. Curida has produced BFS products since 1989 and offers over three decades of know-how in this technology. Customers range from small start-ups and early stage Biotech companies to Big Pharma.

Curida is a part of an exciting and growing life science sector in Norway, and our vision is to be the National Centre for Industrialization of Medical Innovation. Curida is an active partner and member of Oslo Cancer Cluster.

For more information about Curida and our services in manufacturing and development visit www.curida.no

About Dr. René Bommer

Dr. René Bommer is founder and owner of pharmAccel Consulting. He received his Ph.D. in Chemistry from the University of Constance in Germany in 1990. After research positions at the Scripps Clinic in San Diego, USA , at Altana Pharma Germany (now Takeda) and a lectureship at the University of Buenos Aires he joined the device developing and manufacturing company Ing. Erich Pfeiffer GmbH (now Aptar) in Germany and became Director Business Development.

In 2007 he founded his own consulting company focusing on delivery devices and its relevant activities. pharmAccel Consulting delivers to the client a service to support an accelerated entry into the market considering technical, regulatory, marketing and pharmaeconomical aspects of the drug delivery device business. The activities are concentrated on drug products and medical devices intended to be dispensed in liquid or solid forms.

http://pharmaccel.com/